Nflection Therapeutics Inc
Nflection Therapeutics Inc., located in Chestnut Hill, MA, is a clinical-stage biopharmaceutical company dedicated to developing targeted topical therapies for rare dermatological diseases. Their primary focus is on addressing conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks driven by the aberrant activation of the RAS pathway.
The company is advancing its research with first-in-class MEK mitogen-activated protein kinase kinase inhibitors aimed at providing innovative treatment options for patients suffering from RAS-mediated disorders. Through their pipeline, Nflection Therapeutics is committed to changing the landscape of care for affected individuals by 2025.
Generated from the website
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.